NCT05764395 2024-10-10
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Vanderbilt-Ingram Cancer Center
Phase 2 Suspended
Clinical Trials
4 trialsNCT02730884 2020-08-07
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00856791 2017-07-21
Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
Traws Pharma, Inc.
Phase 2 Completed
NCT01807546 2017-06-26
Oral Rigosertib for Squamous Cell Carcinoma
Traws Pharma, Inc.
Phase 2 Completed